RecruitingNot ApplicableNCT05805683

Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury

Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury


Sponsor

Tanta University

Enrollment

50 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This prospective randomized double blinded study will be conducted to evaluate the effect of early pharmacologic intervention with calcitonin on the incidence or the severity of neuropathic pain after spinal cord injury


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma.

Exclusion Criteria5

  • Intake of anticonvulsants medications.
  • Evidence of neuropathic pain.
  • Evidence of previous allergic reaction to calcitonin.
  • Patients with renal, hepatic and cardiac dysfunction or neurological disorders .
  • brain damage or major trauma to extremities or abdomen.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCalcitonin

patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.

DRUGPlacebo

patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.


Locations(1)

Tanta University

Tanta, Gharbia Governorate, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05805683


Related Trials